Loading patent…
AssigneesShanghai Wei Er Biopharmaceutical Technology Co., Ltd., Shanghai Baolong Pharmaceutical Co., Ltd., Baolong Pharmaceutical Co., Ltd., Shanghai Baolong Anqing Pharmaceutical Co., Ltd.
InventorsXin Wu, Youfa Xu, Zhizhe Lin, Yongjie Huang, Jianming Chen, Yuansheng Zhang, Zhiqin Fu, Xinmei Chen, Hang Chen
Estimating the term…
The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-β-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.
A safe and stable nimodipine formulation for injection comprising sulfobutyl ether-β-cyclodextrin and nimodipine,
A safe and stable nimodipine formulation for injection comprising sulfobutyl ether-β-cyclodextrin and nimodipine, wherein the mass ratio of sulfobutyl ether-β-cyclodextrin to nimodipine is 350:1 to 700:1;
Dependencies are inferred from the claim text.